Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
This study is ongoing, but not recruiting participants.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by (Responsible Party):
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01431287
First received: September 8, 2011
Last updated: May 15, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD.
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Disease, Chronic Obstructive |
Drug: tiotropium + olodaterol Drug: tiotropium Drug: olodaterol |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [TOnado TM 2] |
Resource links provided by NLM:
MedlinePlus related topics:
COPD (Chronic Obstructive Pulmonary Disease)
Drug Information available for:
Tiotropium bromide
U.S. FDA Resources
Further study details as provided by Boehringer Ingelheim Pharmaceuticals:
Primary Outcome Measures:
- FEv1 AUC0-3h response [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
- Trough FEV1 response [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
- SGRQ total score (This endpoint will be evaluated after combining the data from this and the replicate study 1237.5) [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- TDI focal score (Key secondary endpoint; This endpoint will be evaluated after combining the data from this and the replicate study 1237.5) [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
- FVC AUC0-3h response [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
- Trough FVC response [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
- FEV1 AUC0-12h response [L] in sub-set of patients with 12-hour PFTs [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
- FEV1 peak0-3 response [L] [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
- FVC peak0-3 response [L] [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
- FVC AUC0-12h response [L] in sub-set of patients with 12-hour PFTs [ Time Frame: 24 weeks treatment ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 2539 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | November 2013 |
| Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: tiotropium+olodaterol high dose FDC
Once daily 2 puffs solution for inhalation Respimat
|
Drug: tiotropium + olodaterol
fixed dose combination
|
|
Experimental: tiotropium+olodaterol low dose FDC
Once daily 2 puffs solution for inhalation Respimat
|
Drug: tiotropium + olodaterol
fixed dose combination
|
|
Active Comparator: olodaterol
Once daily 2 puffs solution for inhalation Respimat
|
Drug: olodaterol
one dose only
|
|
Active Comparator: tiotropium low dose
Once daily 2 puffs solution for inhalation Respimat
|
Drug: tiotropium
low dose or high dose
|
|
Active Comparator: tiotropium high dose
Once daily 2 puffs solution for inhalation Respimat
|
Drug: tiotropium
low dose or high dose
|
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Diagnosis of chronic obstructive pulmonary disease.
- Relatively stable airway obstruction with post FEV1< 80% predicted normal and post FEV1/FVC <70%.
- Male or female patients, 40 years of age or older.
- Smoking history of more than 10 pack years.
Exclusion criteria:
- Significant disease other than COPD
- Clinically relevant abnormal lab values.
- History of asthma.
- Diagnosis of thyrotoxicosis
- Diagnosis of paroxysmal tachycardia
- History of myocardial infarction within 1 year of screening visit
- Unstable or life-threatening cardiac arrhythmia.
- Hospitalization for heart failure within the past year.
- Known active tuberculosis.
- Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years
- History of life-threatening pulmonary obstruction.
- History of cystic fibrosis.
- Clinically evident bronchiectasis.
- History of significant alcohol or drug abuse.
- Thoracotomy with pulmonary resection
- Oral ß-adrenergics.
- Oral corticosteroid medication at unstable doses
- Regular use of daytime oxygen therapy for more than one hour per day
- Pulmonary rehabilitation program in the six weeks prior to the screening visit
- Investigational drug within one month or six half lives (whichever is greater) prior to screening visit
- Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA
- Pregnant or nursing women.
- Women of childbearing potential not using a highly effective method of birth control
- Patients who are unable to comply with pulmonary medication restrictions
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01431287
Hide Study Locations
Hide Study LocationsLocations
| United States, California | |
| 1237.6.01106 Boehringer Ingelheim Investigational Site | |
| Greer, California, United States | |
| United States, Colorado | |
| 1237.6.01120 Boehringer Ingelheim Investigational Site | |
| Fort Collins, Colorado, United States | |
| United States, Connecticut | |
| 1237.6.01131 Boehringer Ingelheim Investigational Site | |
| Danbury, Connecticut, United States | |
| 1237.6.01117 Boehringer Ingelheim Investigational Site | |
| Waterbury, Connecticut, United States | |
| United States, Florida | |
| 1237.6.01118 Boehringer Ingelheim Investigational Site | |
| Deland, Florida, United States | |
| 1237.6.01126 Boehringer Ingelheim Investigational Site | |
| Tampa, Florida, United States | |
| 1237.6.01109 Boehringer Ingelheim Investigational Site | |
| Winter Park, Florida, United States | |
| United States, Georgia | |
| 1237.6.01134 Boehringer Ingelheim Investigational Site | |
| Atlanta, Georgia, United States | |
| United States, Idaho | |
| 1237.6.01107 Boehringer Ingelheim Investigational Site | |
| Couer d'Alene, Idaho, United States | |
| United States, Louisiana | |
| 1237.6.01110 Boehringer Ingelheim Investigational Site | |
| Lafayette, Louisiana, United States | |
| United States, Maryland | |
| 1237.6.01128 Boehringer Ingelheim Investigational Site | |
| Baltimore, Maryland, United States | |
| United States, Massachusetts | |
| 1237.6.01130 Boehringer Ingelheim Investigational Site | |
| North Dartmouth, Massachusetts, United States | |
| United States, Minnesota | |
| 1237.6.01104 Boehringer Ingelheim Investigational Site | |
| Minneapolis, Minnesota, United States | |
| 1237.6.01116 Boehringer Ingelheim Investigational Site | |
| Plymouth, Minnesota, United States | |
| United States, Missouri | |
| 1237.6.01121 Boehringer Ingelheim Investigational Site | |
| St. Louis, Missouri, United States | |
| 1237.6.01123 Boehringer Ingelheim Investigational Site | |
| St. Louis, Missouri, United States | |
| United States, Nevada | |
| 1237.6.01129 Boehringer Ingelheim Investigational Site | |
| Henderson, Nevada, United States | |
| United States, New Jersey | |
| 1237.6.01136 Boehringer Ingelheim Investigational Site | |
| Marlton, New Jersey, United States | |
| United States, New Mexico | |
| 1237.6.01108 Boehringer Ingelheim Investigational Site | |
| Albuquerque, New Mexico, United States | |
| United States, New York | |
| 1237.6.01127 Boehringer Ingelheim Investigational Site | |
| Bayside, New York, United States | |
| 1237.6.01139 Boehringer Ingelheim Investigational Site | |
| Great Neck, New York, United States | |
| United States, North Carolina | |
| 1237.6.01135 Boehringer Ingelheim Investigational Site | |
| Charlotte, North Carolina, United States | |
| United States, Ohio | |
| 1237.6.01114 Boehringer Ingelheim Investigational Site | |
| Cincinnati, Ohio, United States | |
| 1237.6.01102 Boehringer Ingelheim Investigational Site | |
| Columbus, Ohio, United States | |
| United States, Oklahoma | |
| 1237.6.01115 Boehringer Ingelheim Investigational Site | |
| Oklahoma City, Oklahoma, United States | |
| United States, Pennsylvania | |
| 1237.6.01101 Boehringer Ingelheim Investigational Site | |
| Philadelphia, Pennsylvania, United States | |
| United States, Rhode Island | |
| 1237.6.01113 Boehringer Ingelheim Investigational Site | |
| East Providence, Rhode Island, United States | |
| United States, South Carolina | |
| 1237.6.01122 Boehringer Ingelheim Investigational Site | |
| Charleston, South Carolina, United States | |
| 1237.6.01132 Boehringer Ingelheim Investigational Site | |
| Greenville, South Carolina, United States | |
| 1237.6.01137 Boehringer Ingelheim Investigational Site | |
| Greenville, South Carolina, United States | |
| 1237.6.01111 Boehringer Ingelheim Investigational Site | |
| Spartanburg, South Carolina, United States | |
| 1237.6.01105 Boehringer Ingelheim Investigational Site | |
| Union, South Carolina, United States | |
| United States, Texas | |
| 1237.6.01138 Boehringer Ingelheim Investigational Site | |
| Killeen, Texas, United States | |
| 1237.6.01124 Boehringer Ingelheim Investigational Site | |
| McKinney, Texas, United States | |
| United States, Virginia | |
| 1237.6.01112 Boehringer Ingelheim Investigational Site | |
| Richmond, Virginia, United States | |
| 1237.6.01133 Boehringer Ingelheim Investigational Site | |
| Richmond, Virginia, United States | |
| United States, Washington | |
| 1237.6.01125 Boehringer Ingelheim Investigational Site | |
| Spokane, Washington, United States | |
| 1237.6.01103 Boehringer Ingelheim Investigational Site | |
| Tacoma, Washington, United States | |
| Austria | |
| 1237.6.43006 Boehringer Ingelheim Investigational Site | |
| Feldbach, Austria | |
| 1237.6.43005 Boehringer Ingelheim Investigational Site | |
| Gänserndorf, Austria | |
| 1237.6.43002 Boehringer Ingelheim Investigational Site | |
| Innsbruck, Austria | |
| 1237.6.43004 Boehringer Ingelheim Investigational Site | |
| Leoben, Austria | |
| 1237.6.43001 Boehringer Ingelheim Investigational Site | |
| Linz, Austria | |
| 1237.6.43003 Boehringer Ingelheim Investigational Site | |
| Salzburg, Austria | |
| Belgium | |
| 1237.6.32007 Boehringer Ingelheim Investigational Site | |
| Brussel, Belgium | |
| 1237.6.32005 Boehringer Ingelheim Investigational Site | |
| Bruxelles, Belgium | |
| 1237.6.32004 Boehringer Ingelheim Investigational Site | |
| Gent, Belgium | |
| 1237.6.32002 Boehringer Ingelheim Investigational Site | |
| Jambes, Belgium | |
| 1237.6.32009 Boehringer Ingelheim Investigational Site | |
| Lebbeke, Belgium | |
| 1237.6.32001 Boehringer Ingelheim Investigational Site | |
| Leuven, Belgium | |
| 1237.6.32006 Boehringer Ingelheim Investigational Site | |
| Liège, Belgium | |
| 1237.6.32008 Boehringer Ingelheim Investigational Site | |
| Oostende, Belgium | |
| 1237.6.32010 Boehringer Ingelheim Investigational Site | |
| Turnhout, Belgium | |
| Brazil | |
| 1237.6.55013 Boehringer Ingelheim Investigational Site | |
| Botucatu, Brazil | |
| 1237.6.55010 Boehringer Ingelheim Investigational Site | |
| Florianopolis, Brazil | |
| 1237.6.55012 Boehringer Ingelheim Investigational Site | |
| Passo Fundo, Brazil | |
| 1237.6.55005 Boehringer Ingelheim Investigational Site | |
| Porto Alegre, Brazil | |
| 1237.6.55003 Boehringer Ingelheim Investigational Site | |
| Porto Alegre, Brazil | |
| 1237.6.55001 Boehringer Ingelheim Investigational Site | |
| Porto Alegre, Brazil | |
| 1237.6.55002 Boehringer Ingelheim Investigational Site | |
| Porto Alegre, Brazil | |
| 1237.6.55009 Boehringer Ingelheim Investigational Site | |
| Porto Alegre, Brazil | |
| 1237.6.55011 Boehringer Ingelheim Investigational Site | |
| Sao Paulo, Brazil | |
| 1237.6.55007 Boehringer Ingelheim Investigational Site | |
| Sao Paulo, Brazil | |
| 1237.6.55006 Boehringer Ingelheim Investigational Site | |
| Sao Paulo, Brazil | |
| Canada, Alberta | |
| 1237.6.02109 Boehringer Ingelheim Investigational Site | |
| Edmonton, Alberta, Canada | |
| Canada, British Columbia | |
| 1237.6.02111 Boehringer Ingelheim Investigational Site | |
| Vancouver, British Columbia, Canada | |
| Canada, New Brunswick | |
| 1237.6.02106 Boehringer Ingelheim Investigational Site | |
| Moncton, New Brunswick, Canada | |
| Canada, Ontario | |
| 1237.6.02110 Boehringer Ingelheim Investigational Site | |
| Courtice, Ontario, Canada | |
| 1237.6.02101 Boehringer Ingelheim Investigational Site | |
| Downsview, Ontario, Canada | |
| 1237.6.02112 Boehringer Ingelheim Investigational Site | |
| Sarnia, Ontario, Canada | |
| 1237.6.02103 Boehringer Ingelheim Investigational Site | |
| Toronto, Ontario, Canada | |
| 1237.6.02102 Boehringer Ingelheim Investigational Site | |
| Windsor, Ontario, Canada | |
| Canada, Quebec | |
| 1237.6.02104 Boehringer Ingelheim Investigational Site | |
| Point Claire, Quebec, Canada | |
| 1237.6.02105 Boehringer Ingelheim Investigational Site | |
| Sherbrooke, Quebec, Canada | |
| 1237.6.02108 Boehringer Ingelheim Investigational Site | |
| Ste-Foy, Quebec, Canada | |
| China | |
| 1237.6.86117 Boehringer Ingelheim Investigational Site | |
| Baotou, China | |
| 1237.6.86102 Boehringer Ingelheim Investigational Site | |
| Beijing, China | |
| 1237.6.86104 Boehringer Ingelheim Investigational Site | |
| Beijing, China | |
| 1237.6.86105 Boehringer Ingelheim Investigational Site | |
| Beijing, China | |
| 1237.6.86115 Boehringer Ingelheim Investigational Site | |
| Changsha, China | |
| 1237.6.86110 Boehringer Ingelheim Investigational Site | |
| Chengdu, China | |
| 1237.6.86111 Boehringer Ingelheim Investigational Site | |
| Chongqing, China | |
| 1237.6.86109 Boehringer Ingelheim Investigational Site | |
| Haikou, China | |
| 1237.6.86108 Boehringer Ingelheim Investigational Site | |
| Hangzhou, China | |
| 1237.6.86116 Boehringer Ingelheim Investigational Site | |
| Hohhot, China | |
| 1237.6.86114 Boehringer Ingelheim Investigational Site | |
| Jinan, China | |
| 1237.6.86106 Boehringer Ingelheim Investigational Site | |
| Nanjing, China | |
| 1237.6.86101 Boehringer Ingelheim Investigational Site | |
| Shanghai, China | |
| 1237.6.86113 Boehringer Ingelheim Investigational Site | |
| Shenyang, China | |
| 1237.6.86107 Boehringer Ingelheim Investigational Site | |
| Suzhou, China | |
| 1237.6.86112 Boehringer Ingelheim Investigational Site | |
| Xi'An, China | |
| Colombia | |
| 1237.6.57008 Boehringer Ingelheim Investigational Site | |
| Bogota, Colombia | |
| 1237.6.57003 Boehringer Ingelheim Investigational Site | |
| Bogota DC, Colombia | |
| 1237.6.57001 Boehringer Ingelheim Investigational Site | |
| Bogota DC, Colombia | |
| 1237.6.57007 Boehringer Ingelheim Investigational Site | |
| Bogota DC, Colombia | |
| 1237.6.57006 Boehringer Ingelheim Investigational Site | |
| Cali, Colombia | |
| 1237.6.57004 Boehringer Ingelheim Investigational Site | |
| Floridablanca, Colombia | |
| Croatia | |
| 1237.6.38503 Boehringer Ingelheim Investigational Site | |
| Petrinja, Croatia | |
| 1237.6.38504 Boehringer Ingelheim Investigational Site | |
| Rijeka, Croatia | |
| 1237.6.38502 Boehringer Ingelheim Investigational Site | |
| Zadar, Croatia | |
| 1237.6.38501 Boehringer Ingelheim Investigational Site | |
| Zagreb, Croatia | |
| Germany | |
| 1237.6.49022 Boehringer Ingelheim Investigational Site | |
| Aschaffenburg, Germany | |
| 1237.6.49017 Boehringer Ingelheim Investigational Site | |
| Berlin, Germany | |
| 1237.6.49027 Boehringer Ingelheim Investigational Site | |
| Frankfurt, Germany | |
| 1237.6.49026 Boehringer Ingelheim Investigational Site | |
| Frankfurt, Germany | |
| 1237.6.49025 Boehringer Ingelheim Investigational Site | |
| Großhansdorf, Germany | |
| 1237.6.49016 Boehringer Ingelheim Investigational Site | |
| Halle, Germany | |
| 1237.6.49024 Boehringer Ingelheim Investigational Site | |
| Hamburg, Germany | |
| 1237.6.49021 Boehringer Ingelheim Investigational Site | |
| Hannover, Germany | |
| 1237.6.49019 Boehringer Ingelheim Investigational Site | |
| Leipzig, Germany | |
| 1237.6.49028 Boehringer Ingelheim Investigational Site | |
| Mainz, Germany | |
| 1237.6.49018 Boehringer Ingelheim Investigational Site | |
| Rodgau/Dudenhofen, Germany | |
| 1237.6.49020 Boehringer Ingelheim Investigational Site | |
| Schwerin, Germany | |
| 1237.6.49023 Boehringer Ingelheim Investigational Site | |
| Teuchern, Germany | |
| Hungary | |
| 1237.6.36001 Boehringer Ingelheim Investigational Site | |
| Debrecen, Hungary | |
| 1237.6.36004 Boehringer Ingelheim Investigational Site | |
| Gödöllö, Hungary | |
| 1237.6.36005 Boehringer Ingelheim Investigational Site | |
| Pecs, Hungary | |
| 1237.6.36003 Boehringer Ingelheim Investigational Site | |
| Sopron, Hungary | |
| 1237.6.36002 Boehringer Ingelheim Investigational Site | |
| Szeged, Hungary | |
| India | |
| 1237.6.91003 Boehringer Ingelheim Investigational Site | |
| Chennai, India | |
| 1237.6.91011 Boehringer Ingelheim Investigational Site | |
| Coimbatore, India | |
| 1237.6.91004 Boehringer Ingelheim Investigational Site | |
| Jaipur, India | |
| 1237.6.91002 Boehringer Ingelheim Investigational Site | |
| Kolkatta, India | |
| 1237.6.91007 Boehringer Ingelheim Investigational Site | |
| Maharastra, India | |
| 1237.6.91006 Boehringer Ingelheim Investigational Site | |
| Mumbai, India | |
| 1237.6.91009 Boehringer Ingelheim Investigational Site | |
| Nashik, Maharashtra, India | |
| 1237.6.91008 Boehringer Ingelheim Investigational Site | |
| Pune, India | |
| Ireland | |
| 1237.6.35304 Boehringer Ingelheim Investigational Site | |
| County Limerick, Ireland | |
| 1237.6.35303 Boehringer Ingelheim Investigational Site | |
| Dublin 24, Ireland | |
| 1237.6.35301 Boehringer Ingelheim Investigational Site | |
| Dublin 4, Ireland | |
| Japan | |
| 1237.6.81127 Boehringer Ingelheim Investigational Site | |
| Abeno-ku, Osaka, Osaka, Japan | |
| 1237.6.81123 Boehringer Ingelheim Investigational Site | |
| Aoi-ku, Shizuoka, Shizuoka, Japan | |
| 1237.6.81132 Boehringer Ingelheim Investigational Site | |
| Chuo-ku, Kobe, Hyogo, Japan | |
| 1237.6.81121 Boehringer Ingelheim Investigational Site | |
| Fukui, Fukui, Japan | |
| 1237.6.81137 Boehringer Ingelheim Investigational Site | |
| Fukuyama, Hiroshima, Japan | |
| 1237.6.81109 Boehringer Ingelheim Investigational Site | |
| Hachioji, Tokyo, Japan | |
| 1237.6.81134 Boehringer Ingelheim Investigational Site | |
| Himeji, Hyogo, Japan | |
| 1237.6.81106 Boehringer Ingelheim Investigational Site | |
| Hitachi, Ibaraki, Japan | |
| 1237.6.81139 Boehringer Ingelheim Investigational Site | |
| Iizuka, Fukuoka, Japan | |
| 1237.6.81102 Boehringer Ingelheim Investigational Site | |
| Iwamizawa, Hokkaido, Japan | |
| 1237.6.81117 Boehringer Ingelheim Investigational Site | |
| Kamakura, Kanagawa, Japan | |
| 1237.6.81120 Boehringer Ingelheim Investigational Site | |
| Kanazawa, Ishikawa, Japan | |
| 1237.6.81113 Boehringer Ingelheim Investigational Site | |
| Kanazawa, Yokohama, Kanagawa, Japan | |
| 1237.6.81108 Boehringer Ingelheim Investigational Site | |
| Kashiwa, Chiba, Japan | |
| 1237.6.81114 Boehringer Ingelheim Investigational Site | |
| Kawasaki-ku, Kawasaki, Kanagawa, Japan | |
| 1237.6.81135 Boehringer Ingelheim Investigational Site | |
| Kita-ku, Okayama, Okayama, Japan | |
| 1237.6.81126 Boehringer Ingelheim Investigational Site | |
| Kita-ku, Sakai, Osaka, Japan | |
| 1237.6.81101 Boehringer Ingelheim Investigational Site | |
| Kita-ku, Sapporo, Hokkaido, Japan | |
| 1237.6.81136 Boehringer Ingelheim Investigational Site | |
| Kurashiki, Okayama, Japan | |
| 1237.6.81116 Boehringer Ingelheim Investigational Site | |
| Minami-ku, Yokohama, Kanagawa, Japan | |
| 1237.6.81118 Boehringer Ingelheim Investigational Site | |
| Minami-ku, Yokohama, Kanagawa, Japan | |
| 1237.6.81112 Boehringer Ingelheim Investigational Site | |
| Mitaka, Tokyo, Japan | |
| 1237.6.81105 Boehringer Ingelheim Investigational Site | |
| Mito, Ibaraki, Japan | |
| 1237.6.81142 Boehringer Ingelheim Investigational Site | |
| Naha, Okinawa, Japan | |
| 1237.6.81131 Boehringer Ingelheim Investigational Site | |
| Nishi-ku, Kobe, Hyogo, Japan | |
| 1237.6.81104 Boehringer Ingelheim Investigational Site | |
| Obihiro, Hokkaido, Japan | |
| 1237.6.81141 Boehringer Ingelheim Investigational Site | |
| Okinawa, Okinawa, Japan | |
| 1237.6.81110 Boehringer Ingelheim Investigational Site | |
| Ota-ku, Tokyo, Japan | |
| 1237.6.81138 Boehringer Ingelheim Investigational Site | |
| Sakaide, Kagawa, Japan | |
| 1237.6.81103 Boehringer Ingelheim Investigational Site | |
| Sapporo, Hokkaido, Japan | |
| 1237.6.81144 Boehringer Ingelheim Investigational Site | |
| Shimajiri-gun, Okinawa, Japan | |
| 1237.6.81140 Boehringer Ingelheim Investigational Site | |
| Shimajiri-gun, Okinawa, Japan | |
| 1237.6.81145 Boehringer Ingelheim Investigational Site | |
| Shinjuku-ku, Tokyo, Japan | |
| 1237.6.81111 Boehringer Ingelheim Investigational Site | |
| Shinjuku-ku, Tokyo, Japan | |
| 1237.6.81107 Boehringer Ingelheim Investigational Site | |
| Soka, Saitama, Japan | |
| 1237.6.81133 Boehringer Ingelheim Investigational Site | |
| Takarazuka, Hyogo, Japan | |
| 1237.6.81122 Boehringer Ingelheim Investigational Site | |
| Takayama, Gifu, Japan | |
| 1237.6.81143 Boehringer Ingelheim Investigational Site | |
| Tomigusuku, Okinawa, Japan | |
| 1237.6.81128 Boehringer Ingelheim Investigational Site | |
| Toyonaka, Osaka, Japan | |
| 1237.6.81124 Boehringer Ingelheim Investigational Site | |
| Uji, Kyoto, Japan | |
| 1237.6.81130 Boehringer Ingelheim Investigational Site | |
| Yabu, Hyogo, Japan | |
| 1237.6.81129 Boehringer Ingelheim Investigational Site | |
| Yao, Osaka, Japan | |
| 1237.6.81119 Boehringer Ingelheim Investigational Site | |
| Yokosuka, Kanagawa, Japan | |
| Norway | |
| 1237.6.47005 Boehringer Ingelheim Investigational Site | |
| Elverum, Norway | |
| 1237.6.47001 Boehringer Ingelheim Investigational Site | |
| Hønefoss, Norway | |
| 1237.6.47002 Boehringer Ingelheim Investigational Site | |
| Kløfta, Norway | |
| 1237.6.47004 Boehringer Ingelheim Investigational Site | |
| Lierskogen, Norway | |
| 1237.6.47003 Boehringer Ingelheim Investigational Site | |
| Oslo, Norway | |
| 1237.6.47007 Boehringer Ingelheim Investigational Site | |
| SKI, Norway | |
| 1237.6.47008 Boehringer Ingelheim Investigational Site | |
| Svelvik, Norway | |
| Romania | |
| 1237.6.40004 Boehringer Ingelheim Investigational Site | |
| Arad, Romania | |
| 1237.6.40005 Boehringer Ingelheim Investigational Site | |
| Arad, Romania | |
| 1237.6.40001 Boehringer Ingelheim Investigational Site | |
| Bucharest, Romania | |
| 1237.6.40002 Boehringer Ingelheim Investigational Site | |
| Bucuresti, Romania | |
| 1237.6.40003 Boehringer Ingelheim Investigational Site | |
| Cluj, Romania | |
| Russian Federation | |
| 1237.6.07004 Boehringer Ingelheim Investigational Site | |
| Moscow, Russian Federation | |
| 1237.6.07005 Boehringer Ingelheim Investigational Site | |
| Moscow, Russian Federation | |
| 1237.6.07003 Boehringer Ingelheim Investigational Site | |
| St. Petersburg, Russian Federation | |
| 1237.6.07002 Boehringer Ingelheim Investigational Site | |
| St. Petersburg, Russian Federation | |
| 1237.6.07001 Boehringer Ingelheim Investigational Site | |
| Yaroslavl, Russian Federation | |
| Serbia | |
| 1237.6.38105 Boehringer Ingelheim Investigational Site | |
| Belgrade, Serbia | |
| 1237.6.38103 Boehringer Ingelheim Investigational Site | |
| Belgrade, Serbia | |
| 1237.6.38104 Boehringer Ingelheim Investigational Site | |
| Belgrade, Serbia | |
| 1237.6.38102 Boehringer Ingelheim Investigational Site | |
| Kragujevac, Serbia | |
| 1237.6.38101 Boehringer Ingelheim Investigational Site | |
| Nis, Serbia | |
| Slovakia | |
| 1237.6.42101 Boehringer Ingelheim Investigational Site | |
| Bardejov, Slovakia | |
| 1237.6.42102 Boehringer Ingelheim Investigational Site | |
| Bojnice, Slovakia | |
| 1237.6.42104 Boehringer Ingelheim Investigational Site | |
| Kosice, Slovakia | |
| 1237.6.42107 Boehringer Ingelheim Investigational Site | |
| Nitra, Slovakia | |
| 1237.6.42103 Boehringer Ingelheim Investigational Site | |
| Spisska Nova Ves, Slovakia | |
| 1237.6.42106 Boehringer Ingelheim Investigational Site | |
| Zilina, Slovakia | |
| South Africa | |
| 1237.6.27002 Boehringer Ingelheim Investigational Site | |
| Bellville, South Africa | |
| 1237.6.27003 Boehringer Ingelheim Investigational Site | |
| Cape Town, South Africa | |
| 1237.6.27004 Boehringer Ingelheim Investigational Site | |
| Cape Town, South Africa | |
| 1237.6.27001 Boehringer Ingelheim Investigational Site | |
| Cape Town, South Africa | |
| 1237.6.27005 Boehringer Ingelheim Investigational Site | |
| Pretoria, South Africa | |
| Spain | |
| 1237.6.34008 Boehringer Ingelheim Investigational Site | |
| Badalona (Barcelona), Spain | |
| 1237.6.34003 Boehringer Ingelheim Investigational Site | |
| Barcelona, Spain | |
| 1237.6.34009 Boehringer Ingelheim Investigational Site | |
| Barcelona, Spain | |
| 1237.6.34001 Boehringer Ingelheim Investigational Site | |
| Hospitalet de Llobregat, Spain | |
| 1237.6.34002 Boehringer Ingelheim Investigational Site | |
| Mérida, Spain | |
| 1237.6.34005 Boehringer Ingelheim Investigational Site | |
| Pozuelo de Alarcón, Spain | |
| 1237.6.34004 Boehringer Ingelheim Investigational Site | |
| San Juan de Alicante, Spain | |
| 1237.6.34006 Boehringer Ingelheim Investigational Site | |
| Vic (Barcelona), Spain | |
| Sweden | |
| 1237.6.46003 Boehringer Ingelheim Investigational Site | |
| Boden, Sweden | |
| 1237.6.46002 Boehringer Ingelheim Investigational Site | |
| Göteborg, Sweden | |
| 1237.6.46006 Boehringer Ingelheim Investigational Site | |
| Härnösand, Sweden | |
| 1237.6.46005 Boehringer Ingelheim Investigational Site | |
| Höllviken, Sweden | |
| 1237.6.46001 Boehringer Ingelheim Investigational Site | |
| Lund, Sweden | |
| 1237.6.46004 Boehringer Ingelheim Investigational Site | |
| Stockholm, Sweden | |
| 1237.6.46007 Boehringer Ingelheim Investigational Site | |
| Uddevalla, Sweden | |
| Taiwan | |
| 1237.6.88606 Boehringer Ingelheim Investigational Site | |
| Kaohsiung, Taiwan | |
| 1237.6.88608 Boehringer Ingelheim Investigational Site | |
| Kaohsiung, Taiwan | |
| 1237.6.88607 Boehringer Ingelheim Investigational Site | |
| Kaohsiung City, Taiwan | |
| 1237.6.88602 Boehringer Ingelheim Investigational Site | |
| New Taipei City, Taiwan | |
| 1237.6.88604 Boehringer Ingelheim Investigational Site | |
| Taichung, Taiwan | |
| 1237.6.88605 Boehringer Ingelheim Investigational Site | |
| Tainan, Taiwan | |
| 1237.6.88601 Boehringer Ingelheim Investigational Site | |
| Taipei, Taiwan | |
| 1237.6.88603 Boehringer Ingelheim Investigational Site | |
| Taoyuan County, Taiwan | |
| Turkey | |
| 1237.6.90105 Boehringer Ingelheim Investigational Site | |
| Ankara, Turkey | |
| 1237.6.90103 Boehringer Ingelheim Investigational Site | |
| Denizli, Turkey | |
| 1237.6.90104 Boehringer Ingelheim Investigational Site | |
| Istanbul, Turkey | |
| 1237.6.90102 Boehringer Ingelheim Investigational Site | |
| Izmir, Turkey | |
| 1237.6.90101 Boehringer Ingelheim Investigational Site | |
| Izmir, Turkey | |
| United Kingdom | |
| 1237.6.44002 Boehringer Ingelheim Investigational Site | |
| Blackpool, United Kingdom | |
| 1237.6.44009 Boehringer Ingelheim Investigational Site | |
| Blackpool, United Kingdom | |
| 1237.6.44007 Boehringer Ingelheim Investigational Site | |
| Bristol, United Kingdom | |
| 1237.6.44010 Boehringer Ingelheim Investigational Site | |
| Chertsey, United Kingdom | |
| 1237.6.44011 Boehringer Ingelheim Investigational Site | |
| Fleetwood, United Kingdom | |
| 1237.6.44001 Boehringer Ingelheim Investigational Site | |
| Manchester, United Kingdom | |
| 1237.6.44008 Boehringer Ingelheim Investigational Site | |
| Midsomer Norton, United Kingdom | |
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01431287 History of Changes |
| Other Study ID Numbers: | 1237.6, 2009-010669-22 |
| Study First Received: | September 8, 2011 |
| Last Updated: | May 15, 2013 |
| Health Authority: | Austria: Medicines and Medical Devices Agency Belgium: Federal Agency for Medicinal and Health Products Brazil: National Health Surveillance Agency Canada: Health Canada China: Food and Drug Administration Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos Croatia: Agency for Medicinal Product and Medical Devices Germany: Federal Institute for Drugs and Medical Devices Great Britain: Hungary: National Institute of Pharmacy India: Drugs Controller General of India Ireland: Irish Medicines Board Japan: Ministry of Health, Labor and Welfare Mexico: Federal Commission for Protection Against Health Risks Norway: Norwegian Medicines Agency Romania: National Medicines Agency Russia: Pharmacological Committee, Ministry of Health Serbia and Montenegro: Agency for Drugs and Medicinal Devices Slovakia: State Institute for Drug Control South Africa: Medicines Control Council Spain: Spanish Agency of Medicines Sweden: Medical Products Agency Taiwan : Food and Drug Administration Turkey: Ministry of Health United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Chronic Disease Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Disease Attributes Pathologic Processes Respiratory Tract Diseases Tiotropium Parasympatholytics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchodilator Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013